

1           **Comparative study of the chemical composition and anti-proliferative activities of the aerial**  
2           **parts and roots of *Apium graveolens* L. (celery) and their biogenic nanoparticles**

3           Shereen S. T. Ahmed <sup>a,‡</sup>, John Refaat Fahim <sup>a,\*‡</sup>, Khayrya A. Youssif <sup>b</sup>, Mohamed N. Amin <sup>c</sup>,  
4           Hossam M. H. Abdel-Aziz <sup>d</sup>, Ibrahim A. Khadra <sup>e</sup>, Mostafa E. Rateb <sup>f</sup>, Usama Ramadan  
5           Abdelmohsen <sup>a,g</sup>, Ashraf Nageeb Elsayed Hamed <sup>a,\*</sup>

6  
7           <sup>a</sup> Department of Pharmacognosy, Faculty of Pharmacy, Minia University, 61519 Minia, Egypt.

8           <sup>b</sup> Department of Pharmacognosy, Faculty of Pharmacy, Modern University for Technology and  
9           Information, Cairo, Egypt.

10          <sup>c</sup> Department of Biochemistry, Faculty of Pharmacy, Mansoura University, 35516 Mansoura, Egypt.

11          <sup>d</sup> Department of Pharmaceutical Medicinal Chemistry, Faculty of Pharmacy, South Valley University,  
12          Qena, Egypt.

13          <sup>e</sup> Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4  
14          0RE, UK.

15          <sup>f</sup> School of Computing, Engineering & Physical Sciences, University of the West of Scotland, Paisley  
16          PA1 2BE, UK.

17          <sup>g</sup> Department of Pharmacognosy, Faculty of Pharmacy, Deraya University, 61111 New Minia, Egypt.

18  
19          <sup>‡</sup> Authors have equally contributed to this work.

20  
21          \* **Corresponding Authors:**

22          Ashraf Nageeb Elsayed Hamed ([ashrafnag@mu.edu.eg](mailto:ashrafnag@mu.edu.eg))

23          John Refaat Fahim ([john.michael@mu.edu.eg](mailto:john.michael@mu.edu.eg))

24

25

26 **Abstract**

27       Apiaceae plants are multipurpose folk remedies and bioactive foods that show a remarkable ability to  
28 biosynthesize a large number of secondary metabolites with antitumor and chemopreventive potential.  
29 Among the various members of the Apiaceae, celery (*Apium graveolens* L.) has long been used as a  
30 popular edible and medicinal plant owing to its plentiful health benefits and nutraceutical properties;  
31 however, the anticancer potential of this important species has been seldom studied, mostly focusing on  
32 its seeds. Therefore, this work was designed to delve into the chemical composition and anti-proliferative  
33 potential of the total ethanolic extracts of the aerial parts (TEEAGA) and roots (TEEAGR) of *A.*  
34 *graveolens* var. dulce (Mill.) Pers. as well as their green synthesized silver nanoparticles (AgNPs). In  
35 general, both TEEAGA and TEEAGR exhibited moderate to potent inhibitory activities against human  
36 liver (HepG-2), colon (Caco-2), and breast (MCF-7) cancer cell lines, with interesting IC<sub>50</sub> profiles  
37 [(41.37 ± 0.12, 27.65 ± 0.27, and 9.48 ± 0.04 µg/mL) and (11.58 ± 0.02, 7.13 ± 0.03, and 6.58 ± 0.02  
38 µg/mL), respectively] as compared with doxorubicin, while more pronounced anti-proliferative effects  
39 were observed for their biogenic AgNPs, which showed IC<sub>50</sub> values ranging between 25.41 ± 0.16 and  
40 1.37 ± 0.03 µg/mL. Moreover, HPLC–HESI–HRMS-based metabolomics analysis of both extracts  
41 showed the presence of a varied group of secondary metabolites, including flavonoids, phenylpropanoids,  
42 phthalides, coumarins, and sesquiterpenes that further displayed moderate to promising binding affinities  
43 to the active site of cyclin G-associated kinase (GAK), particularly graveobioside A, graveobioside B, and  
44 celeroside C, suggesting their possible contribution as GAK modulators to the anti-proliferative potential  
45 of celery. These findings can help broaden future research on the utilization of different parts of celery  
46 and their NPs as functional foods and medicines in cancer chemoprevention and therapy.

47

48 **Keywords:** Anti-proliferative activity; *Apium graveolens* (celery); Biogenic nanoparticles;  
49 Chemoprevention; Functional foods; Metabolomics analysis; Nutraceuticals.

50

## 51 1. Introduction

52 Cancer has become one of the top health challenges of our current world. Recent epidemiological and  
53 clinical reports have linked the development of several malignancies, e.g. prostate, breast, lung, and colon  
54 cancers with nutrition, defining such pathologies as diet-associated tumors (Deng et al., 2017). Besides  
55 genetic influences, both sedentary lifestyles and modern diet have significantly contributed to the  
56 increasing incidence and mortality rates of different cancers (Anand et al., 2008). These intricate factors  
57 along with the adverse effects and limited efficacy of the currently available chemotherapeutic agents  
58 have called attention to the concept of chemoprevention through the use of herbal phytochemicals and  
59 nutraceuticals to prevent, delay or reverse carcinogenesis (Salimi et al., 2013). Nutraceuticals include  
60 varied groups of secondary metabolites derived from dietary and medicinal plants, and have attracted an  
61 increasing interest in recent years owing to their protective and therapeutic potential against many  
62 degenerative and chronic conditions, e.g. obesity, cardiovascular system disorders, diabetes, Alzheimer's  
63 disease, and cancer. The antioxidant and anti-inflammatory aptitudes of these phytochemicals also afford  
64 an additional benefit of enhancing overall health (Prakash et al., 2013).

65 In view of the growing global demand to explore the chemopreventive role of bioactive foods and  
66 natural plant constituents, several studies have substantiated the potential of Apiaceae plants to reduce the  
67 risk of multiple cancers and to hamper their progression; a fact that also accounts for their common use as  
68 folk medicines, functional foods, as well as food aids and additives (Aćimović, 2017; Aćimović et al.,  
69 2018). Among the various plants of Apiaceae, celery (*Apium graveolens* L.) has long been consumed as a  
70 medicinal food in several forms, either for its characteristic flavor, health promoting effects or medicinal  
71 value (Ingallina et al., 2020). Fresh leaf celery, turnip-rooted celery (celeriac), and celery seeds are  
72 commonly used in flavoring and garnishing purposes as well as for the preparation of a range of food  
73 items, such as salads, salad dressings, soups, stews, sauces, vegetable juices, biscuits, and pickled  
74 vegetables (Aćimović, 2017; Aćimović and Milić, 2017). In herbal medicine, *A. graveolens* is employed

75 as a diuretic, antispasmodic, anti-parasitic, antihypertensive, anti-arthritic, and anti-rheumatic agent. It  
76 also shows helpful sedating effects in nervousness, hysteria, and insomnia (Asif et al., 2011; Fazal and  
77 Singla, 2012; Khairullah et al., 2021). As one of the most important functional species in the Apiaceae,  
78 different extracts of *A. graveolens* have been reported to exhibit many nutraceutical properties  
79 encompassing hypolipidemic, anti-hyperglycemic, anti-platelet aggregation, antimicrobial, laxative,  
80 spasmolytic, gastroprotective, hepatoprotective, cardioprotective, antioxidant, cytotoxic, and anti-  
81 inflammatory effects (Aćimović, 2017; Khairullah et al., 2021; Sowbhagya, 2014). This meritorious  
82 spectrum of health benefits of *A. graveolens* is mainly ascribed to the presence of several classes of  
83 chemical metabolites, including flavonoids, phenolic acids, coumarins, phenols, tannins,  
84 isobenzofuranoids (phthalides), terpenoids, fatty acids, organic acids, polyalcohols, amino acids, and  
85 polysaccharides that have been primarily described from the leaves, petioles, and seeds of the plant  
86 (Aćimović, 2017; Al-Asmari et al., 2017; Ingallina et al., 2020). In contrast, little attention has been paid  
87 to *A. graveolens* roots where some polyacetylenes and phenolic derivatives have been only reported so far  
88 (Al-Asmari et al., 2017; Zidorn et al., 2005). Interestingly, most of the aforementioned groups of  
89 metabolites, such as flavonoids, phthalides, coumarins, polyphenols, terpenoids, and polyacetylenes, have  
90 been reported to possess wide-ranging anticancer and chemopreventive properties, and thus the  
91 consumption of celery was assumed to provide protection against some cancers (Atta, 1998; Aćimović et  
92 al., 2018; Ingallina et al., 2020; Khairullah et al., 2021; Köken et al., 2016). Yet, despite the notable  
93 biological profile of celery plants, their anti-proliferative potential has been limitedly studied, mostly  
94 focusing on the seeds (Al-Jumaily, 2010; Subhadradevi and Kalathil, 2011); therefore, the current study  
95 aims to assess and compare the *in vitro* anti-proliferative activities of the total ethanolic extracts of the  
96 aerial parts (TEEAGA) and roots (TEEAGR) of *A. graveolens* var. *dulce* (Mill.) Pers. against a panel of  
97 human cancer cells, supported with both high-performance liquid chromatography heated electrospray  
98 ionization high-resolution mass spectrometry (HPLC–HESI–HRMS)-based metabolomics and molecular  
99 docking studies in order to explore different metabolites that might contribute to their anti-proliferative

100 potential. Additionally, in light of the growing research on the possible role of nutraceutical nanoparticles  
101 (NPs) in chemoprevention, the anti-proliferative effects of the green synthesized silver nanoparticles  
102 (AgNPs) using TEEAGA and TEEAGR were addressed herein for the first time.

## 103 **2. Materials and methods**

### 104 **2.1. Chemicals and reagents**

105 Dimethyl sulfoxide (DMSO), ethanol (95%), and sodium hydroxide (NaOH) were bought from El-  
106 Nasr Company for Pharmaceuticals and Chemicals, Egypt. Silver nitrate ( $\text{AgNO}_3$ ; purity  $\geq 99.5\%$ ) was  
107 purchased from Sigma-Aldrich, Germany, while acetonitrile (HPLC grade) was obtained from SDFCL sd  
108 fine-Chem Limited, Mumbai, India.

### 109 **2.2. Plant material**

111 *Apium graveolens* L. var. *dulce* (Mill.) Pers. was collected from the farm of Ornamental, Aromatic,  
112 and Medicinal Plants, Faculty of Agriculture, Minia University, Minia, Egypt in April 2018 during the  
113 first year of cultivation. These plants were cultivated in wet clay soil with good drainage under low  
114 humidity and full sun conditions. The plant material was verified by Prof. Mahmoud A. Hassan,  
115 Department of Horticulture, Faculty of Agriculture, Minia University. A voucher specimen (Mn-Ph-Cog-  
116 040) was deposited in the herbarium of Pharmacognosy Department, Faculty of Pharmacy, Minia  
117 University, Egypt.

### 118 **2.3. Preparation of extracts**

119 The collected plant material was left for complete drying in the shade at 24–26 °C and then the roots  
120 were detached from the aerial parts. The air-dried, coarsely powdered aerial parts (700 g) and roots (400  
121 g) of *A. graveolens* were separately macerated with 95% ethanol. The alcoholic solutions were then  
122 concentrated under vacuum till dryness to afford viscous brown extracts [TEEAGA (32.0 g; yield: 4.57%)  
123 and TEEAGR (22.0 g; yield: 5.50%), respectively].

## 124 2.4. Metabolomics analysis

125 Chemical profiling of TEEAGA and TEEAGR was performed by high-performance liquid  
126 chromatography heated electrospray ionization high-resolution mass spectrometry (HPLC–HESI–HRMS)  
127 technique according to the method described by [Mahmoud et al. 2019](#) and [Hamed et al. 2021](#) using a  
128 Dionex UltiMate 3000 HPLC coupled with a Q Exactive™ Hybrid Quadrupole-Orbitrap™ mass  
129 spectrometer. Briefly, 10 µL of each sample (1 mg/mL in methanol) were injected into a Phenomenex  
130 Kinetex column (2.6 µm XB-C18 150 × 4.6 mm) kept at 30 °C and connected with a guard column. A  
131 combination of LC-MS grade water (A) and acetonitrile (B); each containing 0.1% formic acid was used  
132 as the mobile phase. Gradient elution was applied at a flow rate of 500 µL/min, beginning with 5% to  
133 20% B within 2 min, 20% to 98% B within 18 min, 98% B for further 5 min, and finally 98% to 5% B  
134 within 2 min. Positive and negative ionization modes were used for HESI–HRMS analysis applying the  
135 following conditions: capillary temperature (320 °C), sheath gas (57.50), sweep gas (3.25), auxiliary gas  
136 (16.25), spray voltage (+3.5 kV or –2.7 kV), probe heater (462.50 °C), S-Lens RF (50), resolution  
137 (70.000), maximum IT 100 ms, AGC target (1e6), microscans (1), and a scan range of 150–1500 *m/z*.  
138 Differential analysis of mass data was done through [MZmine 2.12](#) and the detected constituents were  
139 annotated by comparison with [METLIN](#) and the Dictionary of Natural Products ([DNP](#)) databases  
140 ([Abdelhafez et al., 2018, 2020a](#); [Ahmed et al., 2021](#); [Hamed et al., 2021](#); [Zahran et al., 2020](#)).

141

## 142 2.5. Green synthesis and characterization of silver nanoparticles (AgNPs)

143 A part of the obtained TEEAGA (10 mg) and TEEAGR (25 mg) were separately dissolved in 1 mL  
144 DMSO and mixed with 1 mL of 0.001 M AgNO<sub>3</sub> and 0.5 mL of 1 N NaOH, then heated for 10 min with  
145 stirring at 60 °C. Subsequently, 0.1 mL of each of TEEAGA and TEEAGR was added to 8 and 4.5 mL of  
146 0.001 M AgNO<sub>3</sub>, respectively, and the final solutions were incubated for 24 h in a dark place at room  
147 temperature and checked for any color change, then kept for further 24 h for stabilization. The synthesis  
148 of AgNPs was confirmed by measuring the UV–Vis spectrum of the reaction mixtures at 200–600 nm

149 using a double beam V-630 spectrophotometer (Jasco, Japan), whereas their morphology and size were  
150 evaluated by a Transmission Electron Microscope (TEM; Jeol model JEM-1010, USA). Fourier-  
151 Transform Infrared Spectroscopy (FT-IR) analysis was also carried out by an FT-IR-8400S  
152 spectrophotometer (IR Prestige-21, IR Affinity-1, Shimadzu, Japan) to detect various biomolecules  
153 involved in the formation and stabilization of the AgNPs ([Abdelhafez et al., 2020b](#); [Ahmed et al., 2021](#)).

154

## 155 **2.6. Anti-proliferative activity**

156 The anti-proliferative effects of both TEEAGA and TEEAGR as well as their biosynthesized AgNPs  
157 (within 72 h after synthesis) were tested and compared against HepG-2 (hepatocellular carcinoma), Caco-  
158 2 (colon carcinoma), and MCF-7 (breast cancer) cell lines obtained from the American Type Culture  
159 Collection (Manassas, VA, USA) using the MTT assay ([Hamed et al., 2021](#); [Mosmann 1983](#); [Samy et al.,](#)  
160 [2016](#)). Cells were initially cultured at 37 °C and 5% CO<sub>2</sub> in DMEM high glucose (Invitrogen/Life  
161 Technologies, USA) supplemented with 10% FBS (Hyclone, USA), 10 µg/mL of insulin (Sigma-Aldrich,  
162 Germany), and 1% penicillin-streptomycin, and then transferred to 96-well plates at a density of  $2.2 \times 10^4$   
163 cell/cm<sup>2</sup>. After overnight incubation, the tested samples were dissolved in DMSO and added to the  
164 cultured cells at different concentrations (20, 30, 40, 50, and 60 µg/mL); the viability of cells was then  
165 examined by the MTT assay on the next day. In short, the cultured cells were treated with 0.5 mg/mL  
166 MTT reagent (150 µL/well) and kept at 37 °C for 3 h. The formed crystals were dissolved by re-  
167 incubation with 150 µL DMSO/well for 1h. A microplate reader (Model 550, Bio-Rad, USA) was used to  
168 measure the absorbance of each plate at 570 nm. The viability baseline was established using DMSO and  
169 the dose-response curve was finally prepared to get the IC<sub>50</sub> values. Doxorubicin (D1515, Sigma-Aldrich,  
170 Germany) was used as a standard. In the same way, AgNPs were added to cells at final concentrations  
171 equivalent to those used in the case of celery extracts, while the viability baseline was adjusted using the  
172 nano-preparation vehicle without extracts.

## 173 2.7. Molecular Docking

174 Molecular docking simulation was performed to predict and evaluate the binding abilities of the  
175 characterized metabolites with the target enzyme cyclin G-associated kinase (GAK). The targeted  
176 compounds were presented in a 2D model using the CHEMDRAW software and copied into the MOE  
177 interface (version 2019.0101) where the energies of the proposed structures were minimized to attain the  
178 most stable conformers that were kept into a database for docking studies. The X-ray crystallographic  
179 structure of GAK in complex with gefitinib (PDB Id: 5Y80) was acquired from the protein data bank  
180 (<https://www.rcsb.org/structure/5Y80>), then validated and prepared for docking analysis (RMSD= 1.8 Å).  
181 Docking simulations were achieved by the MOE dock tool using Triangle Matcher as a placement  
182 scheme, rigid receptor as a refinement scheme, London  $\Delta G$  as a scoring function, in addition to  
183 GBVI/WSAdG as a refinement score. The active site was selected where the original ligand gefitinib  
184 occur and docking was performed in the presence of gefitinib through overlaying.

## 185 2.8. Statistical analysis

187 Data were expressed as mean  $\pm$  standard error of mean. One-way analysis of variance (ANOVA)  
188 followed by Dunnett's test was used. Statistical analysis was carried out by GraphPad Prism software  
189 (Version 5.01, San Diego, CA, USA). Results were described as significant at  $p < 0.05$ .

## 190 3. Results and discussion

### 192 3.1. Metabolomics analysis

193 HPLC–HESI–HRMS analysis of TEEAGA and TEEAGR showed a large degree of similarity between  
194 the metabolic patterns of both extracts and resulted in the annotation of an assortment of chemically  
195 diverse metabolites, e.g. phenylpropanoids, flavonoids, phthalides, coumarins, furanocoumarins, and  
196 sesquiterpenes (Table 1; Fig. 1; [supplementary material Fig. S1 and S2](#)). Through the comparison with the  
197 DNP and METLIN databases, the mass ion peak at  $m/z$  359.136 for the suggested molecular formula



200  $C_{16}H_{24}O_9$  was annotated as the phenylpropanoids, junipediol A 4-*O*-glucoside (**1a**) and/or junipediol A 8-  
201 *O*-glucoside (**1b**). Both of these structural isomers were previously described among the chemical  
202 constituents of *A. graveolens* seeds (Kitajima et al., 2003; Simaratanamongkol et al., 2014), while this is  
203 the first report for their identification from the aerial parts and roots of celery. Likewise, two flavonoidal  
204 biosides, namely luteolin 7-*O*-apiofuranosyl-(1→2)-glucopyranoside (graveobioside A; **2**) and its 3'-  
205 methyl ether (graveobioside B; **3**) were identified from the observed peaks at  $m/z$  579.142 and 593.149,  
206 together with their corresponding molecular formulas  $C_{26}H_{28}O_{15}$  and  $C_{27}H_{30}O_{15}$ , respectively. Both  
207 flavones were characterized in this work from the aerial parts of *A. graveolens* in agreement with Sastri  
208 1956, Liu et al. 2017, and Awad et al. 2019 who reported their bioaccumulation by celery leaves and  
209 seeds, while only graveobioside B (**3**) was detected herein in the roots (Table 1).

210 In the same context, phthalides have been widely found as typical secondary metabolites of Apiaceae  
211 plants, including those in the genus *Apium* (Ingallina et al., 2016; Grube et al., 2019). In this vein, a  
212 dihydrophthalide with the molecular formula  $C_{13}H_{16}O_2$  was characterized as isovalidene-3a,4-  
213 dihydrophthalide (**4**) based on the mass ion peak at  $m/z$  205.123. This compound was earlier reported  
214 among the constituents contributing to the aroma and flavor of *A. graveolens* leaves and stalks (Gold and  
215 Wilson, 1963; Kurobayashi et al., 2006). Further two isomeric hydrophthalides were also identified as  
216 senkyunolide J (**5a**) and/or senkyunolide N (**5b**) in harmony with the observed peak at  $m/z$  225.112 and  
217 the predicted chemical formula  $C_{12}H_{18}O_4$ . Both molecules were obtained before from *A. graveolens* seeds,  
218 showing good inhibitory potential against topoisomerase I and II (Momin and Nair, 2002). Another  
219 hydrophthalide with the molecular formula  $C_{12}H_{20}O_2$  was characterized as 3-butylhexahydrophthalide (**6**)  
220 in line with the mass ion peak at  $m/z$  197.154; this molecule was also formerly described from *A.*  
221 *graveolens* seeds (Barschat et al., 1997). Moreover, in accordance with the reported literature (Al-Asmari  
222 et al., 2017), the current metabolomics study of *A. graveolens* showed the presence of a number of  
223 coumarins, represented by compounds **7–10**. Of these, the mass ion peaks at  $m/z$  405.129, 263.094, and  
224 263.093, corresponding to the chemical formulas  $C_{20}H_{22}O_9$ ,  $C_{15}H_{18}O_4$ , and  $C_{14}H_{14}O_5$ , were described as

223 apiumetin-*O*-glucoside (**7**), 2-(1,2-dihydroxy-1-methylethyl)-2,3-dihydro-7*H*-furo[3,2*g*][1]benzopyran-7-  
224 one (**8**), and celereoin (**9**), respectively. Another related molecule was also characterized as the prenylated  
225 coumarin, osthénol (**10**) on account of the mass ion peak at  $m/z$  229.086 and the molecular formula  
226  $C_{14}H_{14}O_3$ . So far, all of the aforementioned coumarin derivatives have been identified from celery seeds  
227 only (Garg et al., 1981; Maruyama et al., 2009).

228 Beyond the above-mentioned groups, the mass ion peak at  $m/z$  417.247, consistent with the suggested  
229 molecular formula  $C_{21}H_{36}O_8$ , was annotated as celeroside D (**11a**), celeroside C (**11b**), and/or celeroside B  
230 (**11c**); each of these glucosylated eudesmane-type sesquiterpenoids was formerly identified from celery  
231 seeds (Kitajima et al., 2003). Noteworthy, all the identified constituents are firstly reported herein from *A.*  
232 *graveolens* roots.

### 233 234 **3.2. Green synthesis and characterization of AgNPs**

235 Recent developments in nanoparticles' (NPs) research have resulted in enormous applications in food  
236 sciences, medicine, agriculture, and other related fields. Among different forms of NPs, metallic NPs, e.g.  
237 gold and silver NPs, have been proven to display unique physical and chemical attributes owing to their  
238 submicron sizes (1–100 nm), leading to enhanced pharmacological and therapeutic potential (Abdelhafez  
239 et al., 2020, 2021; Hembram et al., 2018). In this respect, plant-mediated synthesis of AgNPs is gaining  
240 prominence because of its cost-effectiveness and eco-friendliness, in addition to the promising biomedical  
241 applications and noteworthy properties of the produced AgNPs, e.g. chemical stability, biocompatibility,  
242 catalytic activity, and biological spectrum which includes anti-inflammatory, antioxidant, antidiabetic,  
243 hepatoprotective, and antimicrobial effects (Hembram et al., 2018; Rao et al., 2016). Such plant-based  
244 AgNPs have been also widely incorporated in cancer research thanks to their privileged antitumor  
245 potential (Alsalihi et al., 2016; Hembram et al., 2018; Rao et al., 2016). Currently, the use of culinary and  
246 medicinal herbs' metabolites as chemopreventive and anticancer nutraceuticals is being limited by many  
247 stability and bioavailability issues, while loading of these chemicals into NPs has been proven to boost

248 their physicochemical and biological behavior, which ultimately enriches their role in combating and  
249 treating cancer (Huang et al., 2010; Li et al., 2015). Prompted by this, we embarked herein on the green  
250 synthesis of AgNPs using *A. graveolens* extracts to study their possible impact on the anti-proliferative  
251 potential of this medicinal species.

252

### 253 **3.2.1. Color change and TEM characterization of AgNPs**

254 The biogenic preparation of TEEAGA- and TEEAGR-based AgNPs was initially observed by the  
255 change of the colorless reaction mixture to a colloidal brown color as the reaction continued  
256 (supplementary material Fig. S3) due to the surface plasmon resonance, indicating the successful  
257 formation of their corresponding AgNPs (Abdelhafez et al., 2020, 2021; Ahmed et al., 2021; Haggag et  
258 al., 2019), while their TEM analysis revealed the formation of spherical particles with mean size ranges of  
259 14.10–25.85 and 15.48–29.12 nm, respectively (Fig. 2).

### 260 **3.2.2. UV–Vis characterization of AgNPs**

261 In agreement with the literature, the UV–Vis spectra of the reaction mixtures of TEEAGA- and  
262 TEEAGR-based AgNPs displayed characteristic absorption maxima at 426 and 425 nm, respectively (Fig.  
263 3), confirming the formation of their respective AgNPs (Abdelhafez et al., 2020, 2021; Ahmed et al.,  
264 2021; Haggag et al., 2019). An increment in the absorption intensities was also noticed on increasing the  
265 added volumes of  $\text{AgNO}_3$ , which is attributed to the change in the particle size of the formed AgNPs  
266 (Tripathy et al., 2010).

### 267 **3.2.3. FT-IR characterization of AgNPs**

314 Medicinal and food plants contain a variety of phytochemicals that can enhance the reduction of  $\text{Ag}^+$   
315 ions to  $\text{Ag}^0$  followed by capping, leading eventually to the formation of stable colloidal NPs. Such is the  
316 case with celery extracts where the availability of structurally diverse metabolites assisted  $\text{Ag}^+$  reduction  
317 and allowed the effective synthesis of biogenic AgNPs. Therefore, FT-IR analysis was employed to

318 evaluate the surface chemistry of the resulting NPs, e.g. chemical bonds and functional atoms, in order to  
319 unveil different biomolecules involved in their formation and stabilization (Ahmed et al., 2021; Hembram  
320 et al., 2018; Youssif et al., 2019). The obtained FT-IR spectra exhibited a number of peaks in relation to  
321 multiple chemical functionalities (Fig. 4 and 5), including those at 3428.81, 2928.38, 2642, 1925.57,  
322 1638.23, 1381.75, 1116.68, 1036.55, 835.99, 772.351, 684.606, 625.788 and 400.70  $\text{cm}^{-1}$  (for AgNPs of  
323 TEEAGA) as well as at 3752.8, 3429.78, 2925.48, 2555.22, 1929.43, 1627.63, 1383.68, 1026.91,  
324 834.062, and 697.141  $\text{cm}^{-1}$  (for AgNPs of TEEAGR), which is in agreement with the reported literature  
325 data (Ahmed et al., 2021; Abdelhafez et al., 2020, 2021; Haggag et al., 2019; Youssif et al., 2019).  
326 Among the aforementioned FT-IR peaks, the absorbance bands at 3755–3550  $\text{cm}^{-1}$  were indicative of the  
327 stretching of free O-H groups in alcohols, while those ranging between 3500 and 3200  $\text{cm}^{-1}$  were  
328 consistent with O-H stretching in alcohols and phenolic compounds with strong hydrogen bonds as well  
329 as the stretching of N-H groups of amines (Abdelhafez et al., 2020; Ahmed et al., 2021; Shameli et al.,  
330 2012). Furthermore, the observed FT-IR peaks at 3100–2500  $\text{cm}^{-1}$  included C-H stretching in alkanes,  
331 alkenes, and aldehydes in addition to O-H stretching of carboxylic acids, whereas those at 2140–1900  $\text{cm}^{-1}$   
332 indicated the stretching of  $\text{C}\equiv\text{C}$  in alkynes and  $\text{C}=\text{C}=\text{C}$  in allenes. Likewise, the absorbance bands at  
333 1800–1560  $\text{cm}^{-1}$  involved the bending of N-H groups in amines and C=C stretching in alkenes, together  
334 with the C=O stretching in a variety of carbonyl compounds, e.g. ketones, aldehydes, carboxylic acids,  
335 lactones, and esters. The observed peaks in the range of 1400–1300  $\text{cm}^{-1}$  were also consistent with the  
336 bending of C-H in alkanes and aldehydes and that of O-H in phenols, alcohols, and carboxylic acids  
337 (Haggag et al., 2019; Youssif et al., 2019). Finally, the FT-IR peaks appearing at 1200–1000  $\text{cm}^{-1}$   
338 corresponded to C-N stretching in amines and C-O stretching in alcohols and aliphatic ethers, whereas  
339 those in the range of 1000–550  $\text{cm}^{-1}$  were assignable to C-Cl stretching, C=C bending in alkenes, and C-H  
340 bending in aromatic compounds (Haggag et al., 2019). The above-mentioned peaks are attributed to the  
341 richness of celery extracts in several chemical principles with varied functional groups, such as  
342 flavonoids, coumarins, chromones, isobenzofurans, phthalides, polyphenols, terpenoids, glycosides,

343 proteins, and polysaccharides, which collectively contribute to the capping and stability of the formed  
344 NPs, preventing their agglomeration (Abdelhafez et al., 2020, 2021; Ahmed et al., 2021; Hembram et al.,  
345 2018; Youssif et al., 2019).

346

### 347 **3.3. Anti-proliferative activity**

348 Prior research has indicated the good inhibitory potential of celery against a variety of cancerous cells,  
349 with most studies being focused on the seeds. In this respect, the cytotoxic activity of the essential oil of  
350 *A. graveolens* var. *filicinum* Crovetto seeds was reported to be attributed to its content of hydrocarbons,  
351 among which the three major components, myrcene, 1,3,8-menthatriene, and limonene displayed potent *in*  
352 *vitro* activities against A-549 (lung carcinoma), HT-29 (colon adenocarcinoma), and MCF-7 cell lines  
353 ( $ED_{50} < 10.2 \mu\text{g/mL}$ ) (Saleh et al., 1998). In a similar fashion, the *n*-hexane extract of *A. graveolens* seeds  
354 was shown to exert higher *in vitro* inhibitory effects on the rhabdomyosarcoma (RD) cell line compared  
355 with its aqueous and ethanolic counterparts, particularly at 200  $\mu\text{g/mL}$  (Al-Jumaily, 2010). The  
356 methanolic seed extract of *A. graveolens* was also found to inhibit the proliferation of DLA (Dalton's  
357 lymphoma ascites) and L929 (mouse lung fibroblast) cancer cells *in vitro* in a concentration-dependent  
358 manner, showing  $IC_{50}$  values of 29.79 and 3.85  $\mu\text{g/mL}$ , respectively (Subhadradevi and Kalathil, 2011). In  
359 another related work, the ethanolic extract of *A. graveolens* affected the viability of human prostatic  
360 carcinoma cells (LNCaP) in both a time- and dose-dependent manner through the induction of apoptosis.  
361 Treatment of LNCaP cells with *A. graveolens* extract has also resulted in downregulation of vascular  
362 endothelial growth factor (VEGF), which is a key mediator of angiogenesis (Köken et al., 2016). More  
363 recently, the total extracts of the leaves and petioles of celery exhibited moderate inhibitory effects (about  
364 33% and 39%, respectively) against *tert*-butyl-hydroperoxide (tBOOH)-induced mutagenicity in the  
365 absence of S9, whereas in the presence of S9, the petiole extract showed higher anti-mutagenic potential  
366 than that of the blade leaves (about 45% and 32% inhibition was observed at 100  $\mu\text{g/mL}$ , respectively).

367 Such effects of celery extracts were assumed to be due to their antioxidant activities or other  
368 desmutagenic mechanisms (Ingallina et al., 2016). Similarly, the essential oil of celery seeds was reported  
369 to prevent CCl<sub>4</sub>-induced genotoxicity possibly due to its antioxidant components, e.g. phenolic acids and  
370 limonene (Sobti et al., 1991). In the same vein, the cytotoxicity of four polyacetylenes, namely  
371 panaxydiol, falcarinol, falcarindiol, and 8-*O*-methylfalcarindiol, obtained from the dichloromethane  
372 extract of root celery was described. Of these, falcarinol displayed the highest inhibitory activity,  
373 especially against acute lymphoblastic leukemia (CEM-C7H2) cells (IC<sub>50</sub>= 3.5 µmol/L) (Zidorn et al.,  
374 2005).

375 In view of the aforementioned data, the anti-proliferative activities of TEEAGA and TEEAGR were  
376 examined herein for the first time in comparison with doxorubicin as a positive control. As illustrated in  
377 Table 2, both extracts inhibited the growth of HepG-2, Caco-2, and MCF-7 tumor cells, with IC<sub>50</sub> values  
378 ranging between 41.37 ± 0.12 and 6.58 ± 0.02 µg/mL. The obtained results also indicated the higher anti-  
379 proliferative potential of TEEAGR against the studied cell lines compared with TEEAGA, with the  
380 utmost activity of both extracts was recorded against MCF-7 cells (IC<sub>50</sub>= 6.58 ± 0.02 and 9.48 ± 0.04  
381 µg/mL, respectively); however, their inhibitory effects were lower than doxorubicin in terms of  
382 IC<sub>50</sub> values (Table 2). In light of the US NCI guidelines, these results interestingly uncover the potent  
383 (IC<sub>50</sub> < 20 µg/mL) to moderate (IC<sub>50</sub>= 21–50 µg/mL) anti-proliferative potential of both celery extracts  
384 against the abovementioned cell lines (Boik, 2001; US NCI guidelines), suggesting the broad anticancer  
385 spectrum of this important medicinal plant and its potential as a chemopreventive functional food.

386 Among the various phytoconstituents identified so far from celery, phthalides have been shown to  
387 possess a protective role against cancer, exemplified by sedanolide and 3-*n*-butylphthalide that exhibited  
388 the ability to stimulate the detoxification enzyme glutathione-*S*-transferase in tumor tissues (Khairullah et  
389 al., 2021). Flavonoids and their glycosylated derivatives, such as those of apigenin, luteolin, and  
390 kaempferol, have been also reported as common phenolics in different varieties of celery (Mencherini et

391 al., 2007; Liu et al., 2017; Yao et al., 2010). The capacity of these flavonoids to combat several types of  
392 cancer through multiple modes of action has been described, including among others, pancreatic, ovarian,  
393 breast, colon, thyroid, leukemia, lung, liver, and prostate cancers (Gates et al., 2009; Hui et al., 2013; Lim  
394 et al., 2012; Shukla and Gupta, 2010). Another class of metabolites, namely coumarins, has been also  
395 shown to contribute to the protective potential of celery against cell mutations by fighting free radicals  
396 (Khairullah et al., 2021). Based on the current investigation of our samples and according to the literature  
397 (Csupor-Löffler et al., 2009; Di Sotto et al., 2018; Iranshahi et al., 2018; Kan et al., 2008; Kawaii et al.,  
398 2001; Liu et al., 2017), the contribution of different phytochemicals, including flavonoids, coumarins,  
399 terpenoids, and phthalides to the anti-proliferative potential of celery can be assumed. Moreover, the  
400 individual composition of each of these chemical classes in the roots and aerial parts of celery along with  
401 their possible synergistic interactions might underlie the different anti-proliferative potencies of TEEAGA  
402 and TEEAGR, which could represent a future research theme in order to correlate such biological effects  
403 to specific chemical principles.

404 On the other hand, a compelling body of evidence has revealed the capacity of nano-sized preparations  
405 to refine the compatibility and effectiveness of natural products against cancer, with those packaged as  
406 NPs were reported to show higher bioefficacy, more targeted actions, fewer side effects, and lower overall  
407 costs than many of the available anticancer drugs (Abdelhafez et al., 2021; Huang et al., 2010; Li et al.,  
408 2015; Rao et al., 2016). Therefore, some phytochemicals of nutraceutical value have been loaded as NPs  
409 to be used in nano-chemoprevention and nano-chemotherapy, e.g. curcumin, lycopene, lutein, quercetin,  
410 and green tea polyphenols (Li et al., 2015; Yadav et al., 2020). Likewise, many studies have substantiated  
411 the nutraceutical and therapeutic properties of various nano-preparations of Apiaceae plants, including  
412 celery (Alsalmi et al., 2016, 2020; Hembram et al., 2018). In this regard, the anti-osteoarthritis, anti-  
413 nociceptive, and antihypertensive potential of celery nanoemulsions were formerly reported (Atta, 1998;  
414 Sowbhagya, 2014), while those prepared using celery oil were shown to exert strong antibacterial actions



415 against *Staphylococcus aureus* and to counteract the growth of oral squamous cell carcinoma (SAS cell  
416 line) *in vitro*, with an  $IC_{50}$  value of 1.4  $\mu\text{L}/\text{mL}$  (Nirmala et al., 2020). The biogenic AgNPs containing  
417 celery leaf extract was also proven to have noteworthy fungicidal potential against the two pathogenic  
418 species, *Aspergillus niger* and *A. wentii* (Roy et al., 2015). From this standpoint, it was of special interest  
419 to explore the anti-proliferative potential of the AgNPs synthesized from the aerial parts and roots of *A.*  
420 *graveolens*. In the main, the AgNPs of both TEEAGA and TEEAGR exhibited more potent inhibitory  
421 effects against the studied tumor cells in comparison with the corresponding celery extracts as inferred  
422 from their remarkably lower  $IC_{50}$  profiles (Table 2), highlighting the possible exceptional role of biogenic  
423 AgNPs in enhancing the antitumor properties of celery. Generally, the cytotoxic effect of AgNPs of  
424 TEEAGR against the tested cell lines was superior to that exerted by their TEEAGA-based counterparts.  
425 Such difference in the potency between TEEAGA- and TEEAGR-based NPs might be underlain by a  
426 number of factors that are known to affect the cytotoxicity of AgNPs, including the composition, shape,  
427 size, surface charge, and capping biomolecules, among others (Kajani et al., 2014). More interestingly, the  
428 inhibitory activities of AgNPs of TEEAGR against HepG-2 cells were largely comparable to doxorubicin  
429 ( $IC_{50} = 1.37 \pm 0.02$  vs.  $1.32 \pm 0.06$ , respectively), whereas their cytotoxic potential against Caco-2 cells  
430 was greater than that of doxorubicin ( $IC_{50} = 1.37 \pm 0.03$  vs.  $2.12 \pm 0.04$ , respectively) (Table 2). These  
431 findings evidently tie well with previous studies wherein a vast array of plant-based AgNPs,  
432 encompassing those biosynthesized from Apiaceae plants, have been proven to exhibit enhanced  
433 antitumor potential, mostly on account of their superior physicochemical and surface properties, large  
434 surface to volume ratio, phytochemical loading aptitude, and targeted cellular interactions (Ahmed et al.,  
435 2021; Alsalhi et al., 2016; Hembram et al., 2018; Yadav et al., 2020). Moreover, according to the  
436 literature, the anticancer effects of AgNPs have been proposed to be triggered by inducing oxidative stress  
437 and DNA damage, suppressing ATP synthesis, regulating signaling pathways, counteracting cell cycle  
438 and proliferation, and promoting apoptotic events (Rao et al., 2016; Xu et al., 2020).



### 439 3.4. Molecular Docking

440 The inhibition of protein kinases has emerged in recent decades as a crucial strategy for cancer  
441 prevention and management owing to their key roles in intracellular signaling which controls cell  
442 proliferation, differentiation, and survival (Ohbayashi et al., 2018). Accumulated data have therefore  
443 highlighted the potential of numerous plant extracts and metabolites, e.g. alkaloids, phenolics, flavonoids,  
444 and terpenoids, to modulate or inhibit different kinases, offering a cornucopia of anticancer drug  
445 candidates (Gill et al., 2020; Hou and Kumamoto, 2010). To date, compounds with anti-protein kinase  
446 activities have shown efficacy against many cancers, exemplified by the clinically approved epidermal  
447 growth factor receptor (EGFR) inhibitor, gefitinib, which is commonly used for the treatment of non-  
448 small cell lung cancer (Ohbayashi et al., 2018), but was also found to be effective against liver, breast, and  
449 colorectal cancers (Geng et al., 2015; Ponz-Sarvisé et al., 2007; Schiffer et al., 2005). Gefitinib not only  
450 interrupts signaling in target cells via EGFR, but also displays high affinity for other protein kinases, e.g.  
451 cyclin G-associated kinase (GAK); a kinase that acts as an important EGFR regulator and contributes to  
452 receptor signaling and other cellular functions (Ohbayashi et al., 2018; Susa et al., 2010). Gefitinib was  
453 also shown to exhibit similar binding modes to the common ATP site in both EGFR and GAK, which  
454 proposes similar mechanisms of inhibition (Ohbayashi et al., 2018). Recently, GAK has been proven as a  
455 potential target for chemoprevention and cancer treatment due to its implication in human malignancy as a  
456 master regulator of tumor proliferation and metastasis (Ohbayashi et al., 2018; Susa et al., 2010). Hence,  
457 in the present study, molecular docking simulation was employed to seek the possible interactions of  
458 metabolites (**1–11**) with GAK using gefitinib as a reference ligand. As depicted in Table 3, most of the  
459 docked compounds formed considerably stable complexes within the catalytic domain of GAK, showing  
460 moderate to favorable binding scores in the range of  $-4.90$  to  $-7.93$  kcal/mol as compared to gefitinib ( $-$   
461  $7.84$  kcal/mol). These bindings were brought about by the interaction with a variety of amino acid  
462 residues, of which Cys126 and Leu46 were equally involved in the interactions shown by many of the  
463 docked metabolites, e.g. **2**, **3**, **6–8**, **11a**, and **11b**, as well as gefitinib (Table 3). Among the docked

464 compounds, the glycosylated derivative of luteolin, graveobioside B (**3**) displayed the highest binding  
465 affinity to GAK through a number of interactions with the key amino acids Leu46, Cys126, and Gln129,  
466 which was even better than gefitinib in terms of its lower energy score ( $-7.93$  kcal/mol), followed by its  
467 demethylated derivative, graveobioside A (**2**) ( $-7.67$  kcal/mol) and the sesquiterpenoid glycoside,  
468 celeroside C (**11b**) ( $-7.24$  kcal/mol); both of them had comparable docking scores to gefitinib ( $-7.84$   
469 kcal/mol) (Table 3; Fig. 6 and 7). These results are broadly in line with the previous reports wherein  
470 flavonoids have been shown to exert varied chemopreventive properties by binding to some kinases,  
471 affecting their phosphorylation state and regulating several signaling pathways involved in carcinogenesis  
472 (Hou and Kumamoto, 2010). In this vein, luteolin and its derivatives have been reported as interesting  
473 molecules against different human malignancies via inhibition of tumor proliferation, driving out  
474 carcinogenic stimuli, stimulation of cell cycle arrest, and induction of apoptosis through  
475 multiple signaling pathways (Imran et al., 2019).

476 Additionally, compounds **1a**, **1b**, **7**, and **11a** showed as good binding aptitudes as the co-crystallized  
477 ligand, gefitinib, with docking scores ranging from  $-6$  to  $-7$  kcal/mol, while **4**, **5a**, **5b**, **8–10**, and **11c**  
478 displayed moderate affinities ( $-5$  to  $-6$  kcal/mol) (Table 3). In contrast, 3-butylhexahydrophthalide (**6**)  
479 exhibited the lowest binding strength ( $-4.90$  kcal/mol) among all the studied phytochemicals. Taken  
480 together, these findings propose the contribution of the characterized metabolites, as possible modulators  
481 of GAK, to the observed anti-proliferative activities of celery extracts against HepG-2, Caco-2, and MCF-  
482 7 cells. The receptor-ligand interactions formed by these molecules, particularly **2**, **3**, and **11b**, might also  
483 afford better insights to design natural therapeutic agents that overcome the side effects of gefitinib.

484

#### 485 **4. Conclusion**

486 The current work described the anti-proliferative activities of the aerial parts and roots of *A. graveolens*  
487 against liver, colon, and breast tumor cells that were shown to be underlain by a diversity of metabolites,  
488 e.g. phenylpropanoids, flavonoids, phthalides, coumarins, and sesquiterpenes, as identified by LC–MS–

489 based metabolomics. Our results also provided evidence for the promising role of nanotechnological  
490 approaches, such as the preparation of biogenic NPs, in enhancing the anticancer and functional properties  
491 of celery. Moreover, molecular docking analysis of the characterized metabolites suggested their  
492 contribution to the anti-proliferative potential of celery extracts as possible inhibitors of GAK, especially  
493 graveobiosides A (**2**) and B (**3**) and celeroside C (**11b**), which revealed prominent interaction aptitudes  
494 with GAK. These data highlight the relevance of different parts of celery and their biogenic NPs for the  
495 development of anticancer functional foods and drugs, and could provide the basis for future *in vivo*  
496 investigations on the anticancer effects of this valued medicinal plant and its secondary metabolites.

#### 497 **Declaration of competing interest**

498 The authors declare no conflict of interest.

499

#### 500 **Funding**

501 This research did not receive any specific grant from funding agencies in the public, commercial, or  
502 not-for-profit sectors.

#### 503 **References**

- 504 [Abdelhafez, O.H., Fawzy, M.A., Fahim, J.R., Desoukey, S.Y., Krischke, M., Mueller, M.J.,](#)  
505 [Abdelmohsen, U.R., 2018. Hepatoprotective potential of \*Malvaviscus arboreus\* against carbon](#)  
506 [tetrachloride-induced liver injury in rats. PloS One 13, e0202362.](#)
- 507 [Abdelhafez, O.H., Othman, E.M., Fahim, J.R., Desoukey, S.Y., Pimentel-Elardo, S.M., Nodwell, J.R.,](#)  
508 [Schirmeister, T., Tawfike, A., Abdelmohsen, U.R., 2020a. Metabolomics analysis and biological](#)  
509 [investigation of three Malvaceae plants. Phytochem. Anal. 31, 204–214.](#)
- 510 [Abdelhafez, O.H., Ali, T., Fahim, J.R., Desoukey, S.Y., Ahmed, S., Behery, F.A., Kamel, M.S., Gulder,](#)  
511 [T., Abdelmohsen, U.R., 2020b. Anti-inflammatory potential of green synthesized silver nanoparticles](#)  
512 [of the soft coral \*Nephthea\* sp. supported by metabolomics analysis and docking studies. Int. J.](#)  
513 [Nanomed. 15, 5345–5360.](#)

- 514 Abdelhafez, O.H., Fahim, J.R., El Masri, R.R., Salem, M.A., Desoukey, S.Y., Ahmed, S., Kamel, M.S.,  
515 Pimentel-Elardo, S.M., Nodwell, J.R., Abdelmohsen, U.R., 2021. Chemical and biological studies on  
516 the soft coral *Nephthea* sp. RSC Adv. 11, 23654-23663.
- 517 Aćimović, M.G., 2017. Nutraceutical potential of Apiaceae. In: Mérillon JM, Ramawat K (eds) Bioactive  
518 molecules in food. Reference Series in Phytochemistry, Springer, Cham.
- 519 Aćimović, M.G., Rat, M.M., Tesevic, V.V., Dojcinovic, N.S., 2018. Anticancer properties of Apiaceae.  
520 Bentham Science, UAE, pp. 236–255.
- 521 Aćimović, M., Milić, N., 2017. Perspectives of the Apiaceae hepatoprotective effects – a review. Nat.  
522 Prod. Commun. 12, 309–317
- 523 Ahmed, S.S.T., Fahim, J.R., Youssif, K.A., Amin, M.N., Abdel-Aziz, H.M.H, Brachmanne, A.O., Piel, J.,  
524 Abdelmohsen, U.R., Hamed, A.N.E., 2021. Cytotoxic potential of *Allium sativum* L. roots and their  
525 green synthesized nanoparticles supported with metabolomics and molecular docking analyses. S. Afr.  
526 J. Bot. 142, 131–139.
- 527 Al-Asmari, A.K., Athar, M.T., Kadasah, S.G., 2017. An updated phytopharmacological review on  
528 medicinal plant of Arab region: *Apium graveolens* Linn. Pharmacog. Rev. 11, 13–18.
- 529 Al-Jumaily, R.M.K., 2010. Evaluation of anticancer activities of crude extracts of *Apium graveolens* L.  
530 seeds in two cell lines, RD and L20B *in vitro*. Iraqi J. Cancer Med. Genet. 3, 18–23.
- 531 Alsalhi, M.S., Devanesan, S., Alfuraydi, A.A., Vishnubalaji, R., Munusamy, M.A., Murugan, K.,  
532 Nicoletti, M., Benelli, G., 2016. Green synthesis of silver nanoparticles using *Pimpinella*  
533 *anisum* seeds: antimicrobial activity and cytotoxicity on human neonatal skin stromal cells and colon  
534 cancer cells. Int. J. Nanomed. 11, 4439–4449.
- 535 Alsalhi, M.S., Devanesan, S., Atif, M., AlQahtani, W.S., Nicoletti, M., Serrone, P.D., 2020. Therapeutic  
536 potential assessment of green synthesized zinc oxide nanoparticles derived from fennel seeds extract.  
537 Int. J. Nanomed. 15, 8045–8057.
- 538 Anand, P., Kunnumakkara, A.B., Sundaram, C., Harikumar, K.B., Tharakan, S.T., Lai, O.S., Sung, B.,  
539 Aggarwal, B.B., 2008. Cancer is a preventable disease that requires major lifestyle changes. Pharm.  
540 Res. 25, 2097–2116.
- 541 Asif, H.M., Akram, M., Usmanghani, K., Akhtar, N., Shah, P., Uzair, M., Ramzan, M., Shah, S.M.,  
542 Rehman, R., 2011. Monograph of *Apium graveolens* Linn. J. Med. Plant. Res. 5, 1494–1496.
- 543 Atta, A., 1998. Anti-nociceptive and anti-inflammatory effects of some Jordanian medicinal plant  
544 extracts. J. Ethnopharmacol. 60, 117–124.

- 545 Awad, H.A., Awda, J.M., Abd-Alssirag, M., Allaalfalahi, D., 2019. GC-mass analysis of (*Apium*  
546 *graveolens*) leaf extracts obtained with aqueous and methanol extraction and study its antimicrobial  
547 activity. Asian J. Microbiol. Biotechnol. Environ. Sci., 21, 84–90.
- 548 Barschat, D., Beck, T., Mosandi, A., 1997. Stereoisomeric flavor compounds. 79. simultaneous enantio-  
549 selective analysis of 3-butylphthalide and 3-butylhexahydrophthalide stereoisomers in celery, celeriac,  
550 and fennel. J. Agric. Food Chem. 45, 4554–4557.
- 551 Boik, J. Natural Compounds in Cancer Therapy, Oregon Medical Press, Princeton, Minn, USA, 2001.
- 552 Csupor-Löffler, B., Hajdú, Z., Zupkó, I., Réthy, B., Falkay, G., Forgo, P., Hohmann, J., 2009.  
553 Antiproliferative effect of flavonoids and sesquiterpenoids from *Achillea millefolium* s.l. on cultured  
554 human tumour cell lines. Phytother. Res. 23, 672–676.
- 555 Deng, F.E., Shivappa, N., Tang, Y., Mann, J.R., Hebert, J.R., 2017. Association between diet-related  
556 inflammation, all-cause, all-cancer, and cardiovascular disease mortality, with special focus on  
557 prediabetics: findings from NHANES III. Eur. J. Nutr. 56, 1085–1093.
- 558 Dictionary of Natural Products. <http://dnp.chemnetbase.com/faces/chemical/Chemical-Search.xhtml>.  
559 Accessed on 17 December 2020.
- 560 Di Sotto, A., Abete, L., Toniolo, C., Mannina, L., Locatelli, M., Giusti, A. M., Nicoletti, M., Vecchiato,  
561 M., Di Giacomo, S., 2018. *Capsicum annum* L. var. Cornetto di Pontecorvo PDO: polyphenolic  
562 profile and in vitro biological activities. J. Funct. Foods 40, 679–691.
- 563 Fazal, S.S., Singla, R.K., 2012. Review on the pharmacognostical and pharmacological characterization  
564 of *Apium graveolens* Linn. Indo Glob. J. Pharm. 2, 36–42.
- 565 Garg, S.K., Sharma, N.D., Gupta, S.R., 1981. A new dihydrofurocoumarin from *Apium graveolens*.  
566 Planta Med. 43, 306–308.
- 567 Gates, M.A., Vitonis, A.F., Tworoger, S.S., Rosner, B., Titus-Ernstoff, L., Hankinson, S.E., Cramer, D.  
568 W., 2009. Flavonoid intake and ovarian cancer risk in a population-based case-control study. Int. J.  
569 Cancer 124, 1918–1925.
- 570 Geng, D., Sun, D., Zhang, L., Zhang, W. 2015. The therapy of gefitinib towards breast cancer partially  
571 through reversing breast cancer biomarker arginine. Afr. Health Sci. 15, 594–597.
- 572 Gill, M.S.A., Saleem, H., Ahemad, N., 2020. Plant extracts and their secondary metabolites as modulators  
573 of kinases. Curr. Top. Med. Chem. 20, 1093–1104.
- 574 Gold, H.J., Wilson, C.W., 1963. The volatile flavor substances of celery. J. Food Sci. 28, 484–488.
- 575 Grube, K., Spiegler, V., Hensel, A., 2019. Antiadhesive phthalides from *Apium graveolens* fruits against  
576 uropathogenic *E. coli*. J. Ethnopharmacol. 237, 300–306.

- 577 Haggag, E.G., Elshamy, A.M., Rabeh, M.A., Gabr, N.M., Salem, M., Youssif, K.A., Samir, A., Bin  
578 Muhsinah, A., Alsayari, A., Abdelmohsen, U.R., 2019. Antiviral potential of green synthesized silver  
579 nanoparticles of *Lampranthus coccineus* and *Malephora lutea*. *Int. J. Nanomed.* 14, 6217–6229.
- 580 Hamed, A., Abdelaty, N.A., Attia, E.Z., Amin, M.N., Ali, T., Afifi, A.H., Abdelmohsen, U.R., Desoukey,  
581 S.Y., 2021. Antiproliferative potential of *Moluccella laevis* L. aerial parts family Lamiaceae  
582 (Labiatae), supported by phytochemical investigation and molecular docking study. *Natural Product*  
583 *Research* 1–5, In press. <https://doi.org/10.1080/14786419.2021.1876046>.
- 584 Hembram, K.C., Kumar, R., Kandha, L., Parhi, P.K., Kundu, C.N., Bindhani, B.K., 2018. Therapeutic  
585 prospective of plant-induced silver nanoparticles: application as antimicrobial and anticancer agent.  
586 *Artif. Cells Nanomed. Biotechnol.* 46(sup3), S38–S51.
- 587 Hou, D.X., Kumamoto, T., 2010. Flavonoids as protein kinase inhibitors for cancer chemoprevention:  
588 direct binding and molecular modeling. *Antioxid. Redox Signal.* 13, 691–719.
- 589 Huang, Q., Yu, H., Ru, Q., 2010. Bioavailability and delivery of nutraceuticals using nanotechnology. *J.*  
590 *Food Sci.* 75, R50–57.
- 591 Hui, C., Qi, X., Qianyong, Z., Xiaoli, P., Jundong, Z., Mantian, M., 2013. Flavonoids, flavonoid  
592 subclasses and breast cancer risk: A meta-analysis of epidemiologic studies. *PLoS ONE* 8, e54318.
- 593 Imran, M., Rauf, A., Abu-Izneid, T., Nadeem, M., Shariati, M.A., Khan, I.A., Imran, A., Orhan, I.E.,  
594 Rizwan, M., Atif, M., Gondal, T.A., Mubarak, M.S., 2019. Luteolin, a flavonoid, as an anticancer  
595 agent: A review. *Biomed. Pharmacother.* 112, 108612.
- 596 Ingallina, C., Capitani, D., Mannina, L., Carradori, S., Locatelli, M., Di Sotto, A., Di, Giacomo. S.,  
597 Toniolo, C., Pasqua, G., Valletta, A., Simonetti, G., Parroni, A., Beccaccioli, M., Vinci, G., Rapa, M.,  
598 Giusti, A.M., Frascchetti, C., Filippi, A., Maccelli, A., Crestoni, M.E., Fornarini, S., Sobolev, A.P.,  
599 2020. Phytochemical and biological characterization of Italian "sedano bianco di Sperlonga" protected  
600 geographical indication celery ecotype: A multimethodological approach. *Food Chem.* 309, 125649.
- 601 Iranshahi, M., Rezaee, R., Najaf Najafi, M., Haghbin, A., Kasaian, J., 2018. Cytotoxic activity of the  
602 genus *Ferula* (Apiaceae) and its bioactive constituents. *Avicenna J. Phytomed.* 8, 296–312.
- 603 Kajani, A.A., Bordbar, A.K., Esfahani, S.H., Khosropour, A.R., Razmjou, A., 2014. Green synthesis of  
604 anisotropic silver nanoparticles with potent anticancer activity using *Taxus baccata* extract. *RSC Adv.*  
605 4, 61394–61403.
- 606 Kan, W. L., Cho, C. H., Rudd, J. A., Lin, G., 2008. Study of the anti-proliferative effects and synergy of  
607 phthalides from *Angelica sinensis* on colon cancer cells. *J. Ethnopharmacol.* 120, 36–43.
- 608 Kawaii, S., Tomono, Y., Ogawa, K., Sugiura, M., Yano, M., Yoshizawa, Y., 2001. The antiproliferative  
609 effect of coumarins on several cancer cell lines. *Anticancer Res.* 21, 917–923.



- 610      Khairullah, A.R., Solikhah, T.I., Ansori, A.N.M., Hidayatullah, A.R., Hartadi, E.B., Ramandinianto, S.C.,  
611      Fadholly, A., 2021. Review on the pharmacological and health aspects of *Apium graveolens* or celery:  
612      An update. *Sys. Rev. Pharm.* 12, 606–612.
- 613      Kitajima, J., Ishikawa, T., Satoh, M., 2003. Polar constituents of celery seed. *Phytochemistry* 64, 1003–  
614      1011.
- 615      Köken, T., Koca, B., Özkurt, M., Erkasap, N., Kuş, G., Karalar, M., 2016. *Apium graveolens* extract  
616      inhibits cell proliferation and expression of vascular endothelial growth factor and induces apoptosis in  
617      the human prostatic carcinoma cell line LNCaP. *J. Med. Food* 19, 1166–1171.
- 618      Kurobayashi, Y., Kouno, E., Fujita, A., Morimitsu, Y., Kubota, K., 2006. Potent odorants characterize the  
619      aroma quality of leaves and stalks in raw and boiled celery. *Biosci. Biotechnol. Biochem.* 70, 958–65.
- 620      Li, C., Zhang, J., Zu, Y.J., Nie, S.F., Cao, J., Wang, Q., Nie, S.P., Deng, Z.Y., Xie, M.Y., Wang, S. 2015.  
621      Biocompatible and biodegradable nanoparticles for enhancement of anti-cancer activities of  
622      phytochemicals. *Chin. J. Nat. Med.* 13, 641–652.
- 623      Lim, Y.D., Cho, J.H., Kim, J., Nho, C.W., Lee, K.W., Park, J., 2012. Luteolin decreases IGF-II  
624      production and downregulates insulin-like growth factor-I receptor signaling in HT-29 human colon  
625      cancer cells. *BMC Gastroenterol.* 12, 9.
- 626      Liu, G., Zhuang, L., Song, D., Lu, C., Xu, X., 2017. Isolation, purification, and identification of the main  
627      phenolic compounds from leaves of celery (*Apium graveolens* L. var. *dulce* Mill. /Pers.). *J. Sep. Sci.*  
628      40, 472–481.
- 629      Mahmoud, B., Hamed, A.N., Samy, M., Abdelmohsen, U.R., Attia, E., Fawzy, M., Refaey, R.H., Salem,  
630      M., Pimentel-Elardo, S., Nodwell, J., Desoukey, S.Y., Kamel, M.R., 2019. Metabolomic profiling and  
631      biological investigation of *Tabebuia aurea* (Silva Manso) leaves, family Bignoniaceae. *Nat. Prod. Res.*  
632      1-6. <https://doi.org/10.1080/14786419.2019.1698571>.
- 633      Maruyama, T., Abbaskhan, A., Choudhary, M.I., Tsuda, Y., Goda, Y., Farille, M., Reduron, J.P., 2009.  
634      Botanical origin of Indian celery seed (fruit). *J. Nat. Med.* 63, 248–253.
- 635      Mencherini, T., Cau, A., Bianco, G., Della Loggia, R., Aquino, R. P., Autore, G., 2007. An extract of  
636      *Apium graveolens* var. *dulce* leaves: Structure of the major constituent, apiin, and its anti-inflammatory  
637      properties. *J. Pharm. Pharmacol.* 59, 891–897.
- 638      METLIN. <http://metlin.scripps.edu/index.php>. Accessed on 15 December 2020.
- 639      Momin, R.A., Nair, M.G., 2002. Antioxidant, cyclooxygenase and topoisomerase inhibitory compounds  
640      from *Apium graveolens* Linn. seeds. *Phytomedicine* 9, 312–318.

- 641 Mosmann, T., 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation  
642 and cytotoxicity assays. *Journal of Immunological Methods* 65, 55–63.
- 643 Mzmine. <http://sourceforge.net/projects/mzmine/>. Accessed on 2 November 2020.
- 644 National Cancer Institute. [https://dtp.cancer.gov/databases\\_tools/docs/compare/compare\\_methodology](https://dtp.cancer.gov/databases_tools/docs/compare/compare_methodology)  
645 .htm. Accessed on 3 October 2021.
- 646 Nirmala, M.J., Durai, L., Gopakumar, V., Nagarajan, R., 2020. Preparation of celery essential oil-based  
647 nanoemulsion by ultrasonication and evaluation of its potential anticancer and antibacterial  
648 activity. *Int. J. Nanomed.* 15, 7651–7666.
- 649 Ohbayashi, N., Murayama, K., Kato-Murayama, M., Kukimoto-Niino, M., Uejima, T., Matsuda, T.,  
650 Ohsawa, N., Yokoyama, S., Nojima, H., Shirouzu, M., 2018. Structural basis for the inhibition of  
651 cyclin G-associated kinase by gefitinib. *ChemistryOpen* 7, 721–727.
- 652 Ponz-Sarvisé, M., Rodríguez, J., Viudez, A., Chopitea, A., Calvo, A., García-Foncillas, J., Gil-Bazo, I.,  
653 2007. Epidermal growth factor receptor inhibitors in colorectal cancer treatment: what's new? *World*  
654 *J. Gastroenterol.* 13, 5877–5887.
- 655 Prakash, D., Gupta, C., Sharma, G., 2012. Importance of phytochemicals in nutraceuticals. *J. Chin. Med.*  
656 *Res. Develop.* 1, 70–78.
- 657 Rao, P. V., Nallappan, D., Madhavi, K., Rahman, S., Wei, L.J., Gan, S.H., 2016. Phytochemicals and  
658 biogenic metallic nanoparticles as anticancer agents. *Oxid. Med. Cell. Longev.* 2016, 3685671.
- 659 Roy, K., Sarkar, C.K., Ghosh, C.K., 2015. *Apium graveolens* leaf extract-mediated synthesis of silver  
660 nanoparticles and its activity on pathogenic fungi. *Digest. J. Nanomater. Biostruct.* 10, 393–400.
- 661 Saleh, M.M., Hashem, F.A., Glombitza, K.W., 1998. Cytotoxicity and *in vitro* effects on human cancer  
662 cell lines of volatiles of *Apium graveolens* var. *filicinum*. *Pharm. Pharmacol. Lett.* 8, 97–99.
- 663 Salimi, A., Seydi, E., Pourahmad, J., 2013. Use of nutraceuticals for prevention and treatment of cancer.  
664 *Iran. J. Pharm. Sci.* 12, 219–220.
- 665 Samy, M.N., Hamed, A.N.E., Sugimoto, S., Otsuka, H., Kamel, M.S., Matsunami, K., 2016.  
666 Officinalioside, a new lignan glucoside from *Borago officinalis*, *Nat. Prod. Res.* 30, 967–972.
- 667 Sastri, B.N., 1956. *The wealth of India. A dictionary of Indian raw materials and industrial products.*  
668 Council of Scientific and Industrial Research, New Delhi.
- 669 Schiffer, E., Housset, C., Cacheux, W., Wendum, D., Desbois-Mouthon, C., Rey, C., Clergue, F., Poupon,  
670 R., Barbu, V., Rosmorduc, O., 2005. Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma  
671 development in the rat liver with cirrhosis. *Hepatology* 41, 307–314.



- 672 Shameli, K., Bin Ahmad, M., Jaffar Al-Mulla, E.A., Ibrahim, N.A., Shabanzadeh, P., Rustaiyan, A.,  
673 Abdollahi, Y., Bagheri, S., Abdolmohammadi, S., Usman, M.S., Zidan, M., 2012. Green biosynthesis  
674 of silver nanoparticles using *Callicarpa maingayi* stem bark extraction. *Molecules* 17, 8506–8517.
- 675 Shukla, S., Gupta, S., 2010. Apigenin: A promising molecule for cancer prevention. *Pharm. Res.* 27, 962–  
676 78.
- 677 Simaratanamongkol, A., Umehara, K., Noguchi, H., Panichayupakaranant, P., 2014. Identification of a  
678 new angiotensin-converting enzyme (ACE) inhibitor from Thai edible plants. *Food Chem.* 165, 92–97.
- 679 Sobti, R.C., Mittal, O.P., Sachdeva, A., Gill, G.B., 1991. Anticlastogenic effect of essential oil of seeds of  
680 *Apium graveolens*. *Cytologia* 56, 303–308.
- 681 Sowbhagya, H.B., 2014. Chemistry, technology, and nutraceutical functions of celery (*Apium graveolens*  
682 L.): an overview. *Crit. Rev. Food Sci. Nutr.* 54, 389–398.
- 683 Subhadradevi, V., Kalathil, K., 2011. Induction of apoptosis and cytotoxic activities of *Apium graveolens*  
684 Linn. using *in vitro* models. *Middle East J. Sci. Res.* 9, 90–94.
- 685 Susa, M., Choy, E., Liu, X., Schwab, J., Hornicek, F. J., Mankin, H., Duan, Z., 2010. Cyclin G-associated  
686 kinase is necessary for osteosarcoma cell proliferation and receptor trafficking. *Mol. Cancer Ther.* 9,  
687 3342–3350.
- 688 The Protein Data Bank. <https://www.rcsb.org/structure/6M8B> (PDB Id: 6M8B). Accessed on 15 March  
689 2021.
- 690 Tripathy, A., Raichur, A.M., Chandrasekaran, N., Prathna, T.C., Mukherjee, A., 2010. Process variables  
691 in biomimetic synthesis of silver nanoparticles by aqueous extract of *Azadirachta indica* (Neem)  
692 leaves. *J. Nanoparticle Res.* 12, 237–246.
- 693 Xu, L., Wang, Y.Y., Huang, J., Chen, C.Y., Wang, Z.X., Xie, H., 2020. Silver nanoparticles: synthesis,  
694 medical applications and biosafety. *Theranostics* 10, 8996–9031.
- 695 Yadav, N., Parveen, S., Banerjee, M., 2020. Potential of nano-phytochemicals in cervical cancer  
696 therapy. *Clin. Chim. Acta* 505, 60–72.
- 697 Yao, Y., Sang, W., Zhou, M., Ren, G., 2010. Phenolic composition and antioxidant activities of 11 celery  
698 cultivars. *J. Food Sci.* 75, C9–C13
- 699 Youssif, K.A., Haggag, E.G., Elshamy, A.M., Rabeh, M.A., Gabr, N.M., Seleem, A., Salem, M.A.,  
700 Hussein, A.S., Krischke, M., Mueller, M.J., Abdelmohsen, U.R., 2019. Anti-Alzheimer potential,  
701 metabolomic profiling and molecular docking of green synthesized silver nanoparticles  
702 of *Lampranthus coccineus* and *Malephora lutea* aqueous extracts. *PLoS ONE* 14, e0223781.
- 703 Zahran, E.M., Abdelmohsen, U.R., Ayoub, A.T., Salem, M.A., Khalil, H.E., Desoukey, S.Y., Fouad,  
704 M.A., Kamel, M.S., 2020. Metabolic profiling, histopathological anti-ulcer study, molecular docking

705 and molecular dynamics of ursolic acid isolated from *Ocimum forskolei* Benth. (family Lamiaceae). S.  
706 Afr. J. Bot. 131, 311–319.

707 Zidorn, C., Jöhrer, K., Ganzera, M., Schubert, B., Sigmund, E., Mader, J., Greil, R., Ellmerer, E.,  
708 Stuppner, H., 2005. Polyacetylenes from the Apiaceae vegetables carrot, celery, fennel, parsley, and  
709 parsnip and their cytotoxic activities. J. Agric. Food Chem. 53, 2518–2523.

710

711

712

713

714

715

716

717

718

719

720

721

722

723

724

725

726

727

728

729

730

731

732

733


734

735


736

737


738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769



**Fig. 1.** Chemical structures of the tentatively characterized metabolites from *A. graveolens*.




**Fig. 2.** TEM photos for the shape and size of AgNPs of TEEAGA (a) and TEEAGR (b).




**Fig. 3.** UV-Vis spectral analysis and color intensity AgNPs of TEEAGA (a) and TEEAGR (b).

806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842




**Fig. 4.** FT-IR spectra of TEEAGA (a) and after synthesis of TEEAGA AgNPs (b).



**Fig. 5.** FT-IR spectra of TEEAGR (a) and after synthesis of TEEAGR AgNPs (b).

843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881



**Fig. 6.** 2D and 3D illustration of the interactions between the targeted compounds and GAK; (A and B): gefitinib and (C and D): graveobioside B.

882

883

884

885

886

887

888

889

890

891

892

893

894

895

896

897

898 **Fig. 7.** 2D and 3D illustration of the interactions between the targeted compounds and GAK; (A and B):

899

celeroside C and (C and D): graveobioside A.

900

